Hepatocellular Carcinoma Clinical Trial
Official title:
The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study
Many investigators have studied for prevention and care of Hand-Foot Skin Reaction(HFSR), and
urea cream is typical representative. Recent study was performed prevention effect of urea
cream for Hand-Foot Skin Reaction(HFSR) on 871 Chinese. But the study did not designed as
placebo-control group and it had big defect in double-blinded.
Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect
of urea cream on Korean patient group.
Sorafenib is multiple tyrosine kinase inhibitor. It blocks path that such as Raf-1, Vascular
Endothelial Growth Factor Receptor (VEGFR), Platelet-Drived Growth Factor Receptor-β
(PDGFR-β), c-Jit, Flt-3. Sorafenib was known to increase life rate about processed
hepatocellular carcinoma. So it is advised as standard treatment for liver cancer patient who
has processed Barcelona Clinic Liver Cancer (BCLC) disease period C.
Sorafenib related side effect has reported such as fatigue, diarrhea, vomit, nausea,
pruritus, depilation, Hand-Foot Skin Reaction(HFSR). Among the symptoms, Hand-Foot Skin
Reaction(HFSR) is the most occurrence after using sorafenib and major reason of drug dose
de-escalation, it function as decrease anti-cancer effect of sorafenib. It is known for the
reason of Hand-Foot Skin Reaction(HFSR) occurrence is caused by tyrosine kinase inhibitive
action, and its characteristic symptom is known as keratocyte necrosis, dermal edema,
parakeratosis, hyperkeratosis. The level is categorized grade 1,2,3 according to the
severity.
The result of meta-analysis of 24 clinical trials that contained 6000 patients, Hand-Foot
Skin Reaction(HFSR) occured 39% of sorafenib used patients and 9% of total patients had grade
3 Hand-Foot Skin Reaction(HFSR). But prevalence rate on hepatocellular carcinoma patients who
used sorafenib is about 51% on Japanese, 45% on Asia-pacific patient (inclusive Korean) and
73.6% on Chinese. Prevalence rate of Hand-Foot Skin Reaction(HFSR) is different from result
of each study, but about 50% of sorafenib used patients has had Hand-Foot Skin Reaction(HFSR)
generally and Asian has more higher degree of prevalence rate. Therefore, prevent and care of
Hand-Foot Skin Reaction(HFSR) on Korean hepatocellular carcinoma patients who used sorafenib
is required.
Urea cream is typical representative for prevention and care of Hand-Foot Skin
Reaction(HFSR). As stability-guaranteed drug, it is relatively cheap, locally affect and has
used for psoriasis treatment. Also it is known for curative effacement on Hand-Foot Skin
Reaction(HFSR) after use tyrosine kinase inhibitor such as sorafenib, sunitinib.
Therefore, it needs complementary study as double-blinded placebo-controlled trial and effect
of urea cream on Korean patient group.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |